جستجوی مقالات مرتبط با کلیدواژه "لواستاتین" در نشریات گروه "زیست شناسی"

One of the ways to reduce cholesterol is to use statins that prevent cholesterol synthesis. The statins are similar to mevalonate and act as a competitive inhibitor of HMG-CoA reductase enzyme. Lovastatin is the eminent derivate of the statins group, which is produced by many microorganisms. At commercial scale lovastatin is produced in submerged culture by Aspergillus terreus. The industrial production of this metabolite is carried out by Aspergillus turosus in liquid culture. The main aim of this research was to investigate the effect of spore age on lovastatin production at the inoculation stage; also, the impact of adding olive oil and tetracycline as inducers for lovastatin production were examined. In the present experimental research, different suspensions from varying ages of spore were prepared and added to the medium of Aspergillus terreus ATCC 20542; lovastatin concentration also was measured by High Performance Liquid Chromatography (HPLC). Findings: The utmost lovastatin was observed in inoculum with 85 days spore age and equal to 60 mg/l, which was approximately twice higher compared to when inoculated with 10 days spore age. The best concentration of spore inoculation was 0.5×107 spores/ml. Lovastatin production significantly increased when tetracycline and olive oil were used as inducers. As the inoculated spore age increases, lovastatin and biomass production is increased. The lovastatin production is increases by more than 1.5 times while adding tetracycline and olive oil compared to date syrup alone.

Lovastatin is a potent agent for lowering cholesterol of blood. Since one of the main reasons of mortality in developing countries is cardiovascular disease، which is caused by precipitation of fatty acid (especially cholesterol) in blood vessels; therefore diets containing lovastatin may prevent this type of disease. In this study، Lovastatin، monacolin K or competitive inhibitor of the HMG-CoA reductase (operative enzyme for cholesterol synthesis) was produced by submerged fermentation using Monascus purpureus PTCC5303. Seven chemical and nutritional parameters including maltose، peptone، MgSO4. 7H2O، MnSO4. H2O، KH2PO4، thiamin and pH screened using Plackett Burman experimental design for monacolin production. Among different parameters، maltose and MgSO4. 7H2O showed significant effect on biomass and monacolin production. The concentration of these agents were optimized using response surface methodology for lovastatin production in the shaker flask. The optimized medium contained 26 g/L maltose، 5 g/L peptone، 0. 1 g/L MgSO4. 7H2O، MnSO4. H2O 0. 5 g/L، 4 g/L KH2PO4، Vitamin B1 0. 1 g/L and pH 7. After 10 days of fermentation in the shaker flask with 130 rpm agitation and 30 ºC، we achieved maximum lovastatin production which was 63 mg/l.

Cardiovascular diseases and atherosclerosis are the leading cause of mortality and morbidity around the world. Inflammation and coagulation are two important risk factors of Cardiovascular disease. In this study, the effect of hydroalcoholic extract of Hypericum perforatum on inflammatory and coagulation factors in hypercholesterolemic rabbits was studied and its effect was compared with lovastatin. 25 adult male Newzeland rabbits were randomly divided into five groups of five and were fed for 60 days as follows: basic diet, high cholesterol, basic diet along with Hypericum extract (150mg/kg), high cholesterol along with Hypericum extract (150mg/kg) and high cholesterol along with lovastatin (10mg/kg). Blood samples were taken at the beginning, one month later and at the end of the study in order to measure their serum factors. The result showed that both the extract and lovastatin reduced significantly C-reactive protein (CRP), white blood cell(WBC), fibrinogen and platelet compared with high cholesterol group. Therefore Hypericum by decreasing inflammation and coagulation risk factor cause prevention of atherosclerosis also results showed that the extract in more effective to decrease cardiovascular risk factor than lovastatin.